Navigation Links
ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
Date:5/20/2009

HALIFAX, May 20 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has announced a collaboration agreement with the National Research Council Institute for Biodiagnostics (NRC-IBD) Atlantic. This collaboration will develop new 3-D MRI technology to track the effect of IVT's DepoVax(TM) technology on reducing tumour growth.

"This research has the potential to deliver extremely sensitive MRI analysis, down to the individual cell level, and we will see, for the first time, our DepoVax(TM) formulation in action," remarked Dr. Marc Mansour, vice president R&D at IVT.

In pre-clinical studies, IVT has shown that DepoVax(TM) vaccines can eradicate cancerous tumors. This new research involves labeling liposomes, suspended in the DepoVax(TM) formulation, with iron-oxide nanoparticles. The 3-D MRI analysis will shed light on the activity of DepoVax(TM) in vivo, and allow the monitoring of tumor elimination in real time.

Current MRI techniques are well established in biomedical research. This research aims at developing highly sensitive and quantitative techniques for monitoring tumor progression and vaccine clearance in vivo.

"This collaboration means that NRC-IBD Atlantic will break new ground in developing novel MRI imaging techniques that will vastly improve the quality of information that may be acquired non-invasively," continued Mansour.

ABOUT IVT

Most recently, ImmunoVaccine Technologies presented significant advancements in its therapeutic cancer, pandemic influenza and Hepatitis B vaccine applications at BIO 2009 international convention www.convention.bio.org.

ImmunoVaccine Technologies Inc., is a privately held, vaccine development company. Through its own biotech research, patented DepoVax(TM) technology, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world. www.immunovaccine.com.


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
2. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
3. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
4. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
5. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
6. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
7. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
10. GenVault Receives Four Critical U.S. and E.U. Patent Allowances for Key Biosample Management Technologies
11. MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
Breaking Biology News(10 mins):